Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.70 |
| ▸ | HTR2A | P28223 | 10/20 | 0.68 |
| ▸ | HTR1A | P08908 | 8/20 | 0.61 |
| ▸ | HTR2C | P28335 | 6/20 | 0.61 |
| ▸ | HTR2B | P41595 | 6/20 | 0.61 |
| ▸ | HTR1B | P28222 | 4/20 | 0.58 |
| ▸ | HTR1D | P28221 | 3/20 | 0.58 |
| ▸ | HTR1E | P28566 | 2/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.58 |
| ▸ | HTR5A | P47898 | 2/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | HTR1F | P30939 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14907378 | 0.95 | HTR6 (0.67) | HTR6HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL14907380 | 0.95 | HTR6 (0.67) | HTR6HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL14961128 | 0.94 | HTR6 (0.71) | HTR6HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL14961154 | 0.88 | HTR2A (0.54) | HTR6HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL15678352 | 0.87 | HTR2A (0.56) | HTR6HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL26307748 | 0.86 | HTR6 (0.56) | HTR6HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL24168706 | 0.85 | HTR2A (0.66) | HTR6HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL30249003 | 0.85 | HTR2A (0.61) | HTR6HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL14907357 | 0.84 | HTR2A (0.68) | HTR6HTR2AHTR1AHTR2CHTR1B | |
| SCHEMBL26323232 | 0.84 | HTR2A (0.63) | HTR6HTR2AHTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| WO-2013063492-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR6 12/4885HTR2A 34/4885HTR1A 38/4885 |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR6 12/4885HTR2A 34/4885HTR1A 38/4885 |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR6 12/4885HTR2A 34/4885HTR1A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.